Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 2, 2020

View Archived Issues

BioLineRx stops enrolling patients in GENESIS study based on positive interim data

FDA clears IND for phase IIa study of OLX-10010 for hypertrophic scars

Study links two ALS mechanisms

Researchers present HER2-targeting affibody-drug conjugates for the treatment of ovarian cancer

Preclinical data support ongoing clinical development of ASTX-029

EpCAM-targeting PDC shows efficacy and safety in cancer models

Preliminary PK profile of VIR-2482 suggests once-per-season dosing against influenza A

INSERM and collaborators describe hematopoietic stem cells including beta globin gene

Sichuan Kelun-Biotech Biopharmaceutical discovers CCR2/CCR5 antagonists

Clinical trial begins in Brazil with nasally administered foralumab for COVID-19

Jiangsu Hansoh Pharmaceutical Group and collaborators patent dual GIP-R/GLP-1 agonists

FDA allows InnoCare's IND for phase II evaluation of orelabrutinib in MS

New RET inhibitors identified at Zhejiang Hisun Pharmaceutical

PRIMEGENE BEIJING discovers TYK2 inhibitors

Akeso reports phase Ia data on PD-1/VEGF bispecific antibody AK-112

Leo Pharma presents pooled safety data from clinical trials of tralokinumab

Genentech's antibody-antibiotic conjugate compared to SOC antibiotics in S. aureus

AstraZeneca reports data from steroid-sparing trial of Fasenra in severe asthma

Amryt presents data from pivotal EASE study of Filsuvez in epidermolysis bullosa

FDA approves IND for TaiGen's pan-influenza antiviral TG-1000

IDMC recommends modification of REGN-COV2 trial in hospitalized COVID-19 patients

Bellicum reports interim data on BPX-601 in relapsed/refractory metastatic pancreatic cancer

New phase II data presented from BRAVE-AA1 trial of baricitinib in alopecia areata

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...